Industry Overview - The recent passage of a new bill that reverses the 2018 Farm Bill has created uncertainty for marijuana stock investors, as it alters the legal landscape for hemp and cannabis operators in the U.S. [1][2] - This legislative change is viewed as a potential setback for the industry, raising questions about the future of legal cannabis operations and the preservation of cannabis genetics [2]. Impact on Marijuana Stocks - The effect of the new bill on marijuana stock trading and investment remains uncertain, but there is speculation that federal reform could lead to increased government control similar to that of tobacco and alcohol industries [3]. - Despite the challenges posed by the new legislation, there are still notable marijuana stocks that investors are encouraged to monitor for potential growth if federal reform is enacted [3]. Company Highlights - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products, with recent financial results indicating a strong operational presence [4]. - **Cronos Group Inc.**: Focuses on the cultivation and marketing of cannabis products, reporting significant earnings in its Q2 2025 results [7]. - **SNDL Inc.**: Reports a 9% increase in net revenue quarter-over-quarter and a 6% increase year-over-year in Q3 2025, achieving record levels of consolidated net revenue and gross profit [11][14]. Financial Performance - Aurora Cannabis reported a 15% year-over-year increase in global medical cannabis net revenue, reaching $70.5 million, with a 52% growth in Adjusted EBITDA to $15.4 million [9]. - SNDL's Q3 2025 financial results showed net revenue of $244.2 million, reflecting a growth rate of 3.1%, and a gross profit of $64.2 million, representing a 1.9% increase year-over-year [15].

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a moderate growth ranking despite weaker trends across all timeframes, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which viewed the hemp-derived product segment as a key entry point into the U.S. market [8].

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a weaker price trend across all timeframes but a moderate growth ranking, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which had aimed to enter the U.S. market through hemp-derived products [8].

Core Insights - The cannabis industry is showing strong profitability, with both multi-state operators (MSOs) and ancillary companies thriving in the market [1][2] - Despite the overall success in the cannabis sector, public marijuana stocks have not performed similarly, often influenced by political updates and reform issues [2][3] - A long-term investment strategy focusing on companies adapting to market volatility is recommended for potential profitability [2][3] Company Summaries - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products in Canada and internationally. Recently invested in a German manufacturing facility to enhance growth capacity and product quality [4][6][7] - **Cronos Group Inc.**: Operates in the cultivation, production, and marketing of cannabis products in Canada and internationally. Recently launched a new product line, SOURZ by Spinach®, which offers a variety of liquid diamond-infused gummies [8][9][11] - **SNDL Inc.**: Focuses on the production and sale of cannabis products for the adult-use market in Canada. Reported a record net revenue for its Cannabis Retail segment and significant growth in operating income [8][13][14]

Core Insights - SNDL Inc. has seen a significant increase in investment from Goldman Sachs, raising its position by 17.1% in Q1, now holding 424,317 shares valued at $598,000 [1] - The company's year-to-date return of 30.17% significantly outperforms the market average return of 12.96% [2] - SNDL is expanding its cannabis retail operations internationally, particularly in the U.K. and Continental Europe, which is expected to drive additional revenue [3] Company Overview - SNDL Inc. is a Canadian company involved in the development, distribution, and marketing of cannabis products for the adult-use market, operating through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments [4]

Market Overview - U.S. stocks exhibited mixed performance, with the Nasdaq Composite increasing by over 100 points on Monday [1] - Cannabis-linked stocks experienced significant gains following President Trump's video promoting the health benefits of cannabis [1] Company Highlights - Tilray Brands, Inc. (NASDAQ: TLRY) saw a sharp increase in shares, rising 39.2% to $1.5983 [1] - Merus N.V. (NASDAQ: MRUS) gained 36.6% to $94.14 after Genmab agreed to acquire the company for $97 per share [4] - Better Home & Finance Holding Company (NASDAQ: BETR) increased by 20.1% to $63.60, supported by a $75 million at-the-market offering for Class A shares [4] - BTQ Technologies Corp. (NASDAQ: BTQ) jumped 20% to $6.36, as Danal began proof-of-concept for BTQ's quantum-secure Stablecoin settlement network [4] - SNDL Inc. (NASDAQ: SNDL) rose 18.8% to $2.77, benefiting from the positive sentiment around cannabis stocks [4] - Innoviz Technologies Ltd. (NASDAQ: INVZ) increased by 15.6% to $1.9701 after Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $1.50 to $2.50 [4] - Sandisk Corporation (NASDAQ: SNDK) shares jumped 14.3% to $111.06 [4] - GDEV Inc. (NASDAQ: GDEV) rose 12.7% to $29.24 [4] - Ondas Holdings Inc. (NASDAQ: ONDS) gained 12.2% to $8.59 [4] - Pony AI Inc. (NASDAQ: PONY) increased by 10.3% to $23.36, with Citigroup initiating coverage with a Buy rating and a price target of $29 [4] - Galaxy Digital (NASDAQ: GLXY) gained 9.5% to $33.85 [4] - Western Digital Corporation (NASDAQ: WDC) rose 9% to $116.48 after Rosenblatt raised its price target from $90 to $125 while maintaining a Buy rating [4] - New Oriental Education & Technology Group Inc. (NYSE: EDU) increased by 5% to $53.85, with B of A Securities maintaining a Buy rating and raising the price target from $56.2 to $58.2 [4] - GLOBALFOUNDRIES Inc. (NASDAQ: GFS) rose 5% to $37.40 following a collaboration announcement with Corning for developing detachable fiber connector solutions [4]

Core Viewpoint - President Donald Trump's recent video on Truth Social has reignited interest in cannabis, particularly its potential health benefits and the possibility of changes in federal drug policy [1][2]. Group 1: Health Benefits of Cannabis - The video, produced by The Commonwealth Project, advocates for CBD to be covered under Medicare, labeling it as "the most important senior health initiative of the century" [2]. - It claims that CBD could slow disease progression and serve as an alternative to many prescription drugs for older adults, potentially saving the healthcare system $64 billion annually if cannabis is fully integrated [2]. Group 2: Federal Policy Implications - Trump's video follows earlier comments indicating that his administration is considering reclassifying cannabis at the federal level, which could lead to reduced criminal penalties and eased operational restrictions for cannabis businesses [2]. Group 3: Market Reaction - The announcement led to a significant rally in cannabis stocks, with Canopy Growth Corp. rising 15% and Tilray Brands, Inc. surging 35% [3]. - Other companies such as Cronos Group, Inc., SNDL Inc., and Aurora Cannabis, Inc. also saw increases of over 20% [3]. - The AdvisorShares Pure US Cannabis ETF experienced a nearly 20% increase, reflecting the overall positive market sentiment towards the cannabis sector [4].

Industry Overview - The Canadian cannabis sector is a focal point for investors as it continues to evolve with expanding operations and long-term growth strategies [1][3] - The U.S. cannabis industry has surpassed $33 billion in annual sales, with projections exceeding $50 billion by 2030, indicating significant global opportunities for Canadian companies [1] - Recent developments in U.S. legalization discussions, including potential federal rescheduling of cannabis, could enhance banking access and reduce tax burdens, fostering optimism for both U.S. and Canadian firms [1][2] Company Summaries Cronos Group (CRON) - Cronos Group focuses on research, development, and global distribution, emphasizing branded products and international medical cannabis opportunities rather than a large U.S. dispensary network [4][7] - The company reported revenue of approximately CAD $33.5 million, a 20% year-over-year increase, but also a net loss of about CAD $38.5 million due to foreign-exchange headwinds and investment costs [7] - Cronos has improved gross margins and maintains a strong liquidity position, allowing for strategic flexibility and potential growth in global medical markets [7] SNDL Inc. (SNDL) - SNDL has established one of the largest retail footprints in Canada, operating over 180 retail locations under various banners, while also pursuing investments in the U.S. market [8][10] - The company reported net revenue of approximately CAD $244.8 million, with a gross profit increase of over 16% and positive operating income of around CAD $5 million for the first time in several years [10] - SNDL's strong cash position of over CAD $200 million and no debt on its balance sheet provide financial stability, while its strategy focuses on expanding its retail network and preparing for cross-border opportunities [10] Aurora Cannabis (ACB) - Aurora Cannabis emphasizes medical cannabis exports and global distribution, serving regulated medical markets in Europe and Australia, while shifting away from low-margin recreational cannabis [11][13] - The company reported total net revenue of about CAD $81 million, reflecting nearly 30% growth year-over-year, with medical cannabis sales increasing over 40% to more than CAD $61 million [13] - Aurora's adjusted gross margins improved to roughly 54%, showcasing higher profitability from its medical and international operations, despite challenges from regulatory shifts and competition [13] Investment Considerations - Investors should monitor the financial performance, operational strategies, and regulatory changes affecting Cronos Group, SNDL, and Aurora Cannabis, as each company presents unique opportunities and risks in the evolving cannabis landscape [14]

Group 1 - SNDL Inc. reported Q2 2025 net sales of $244.8 million, a 7.3% year-over-year increase, driven by a 17.4% growth in its cannabis business and a recovery in its liquor retail division [1] - The company achieved an operating income of $5.0 million, with a gross profit of $67.6 million, reflecting a 16.2% increase and a gross margin of 27.6% [1] - SNDL Inc. had no debt and $208.2 million in unrestricted cash at the end of the quarter, despite a negative free cash flow of $7.9 million due to working capital investments and CAPEX [1] Group 2 - CEO Zach George highlighted that Q2 marked the first positive operating income and net earnings for SNDL Inc. [2] - Strategic initiatives included a $32.2 million agreement to acquire 32 cannabis outlets, the launch of the Rise Rewards loyalty program, and a $9.5 million CAPEX investment for retail expansion [2] - The company has increased exports to the UK and EU while developing its U.S. strategy, positioning itself as one of the best marijuana stocks [2]

Industry Overview - The cannabis sector has experienced significant volatility and downtrends, making it challenging for investors to achieve decent returns [1][2] - Despite these challenges, the cannabis industry is progressing and remains profitable, with growing markets in Europe, Canada, and parts of South America [2][3] - Recent trading indicates a potential resurgence in the cannabis sector, driven by ongoing federal reform efforts in the USA [3] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, distribution, and marketing of cannabis products internationally. Reported Q2 2025 earnings on August 7 [4] - **SNDL Inc.**: Focuses on the production, distribution, and sale of cannabis products for the adult-use market in Canada. Announced its 2025 Annual and Special Meeting of Shareholders at the end of July [5][7] - **Aurora Cannabis Inc.**: Involved in the production, distribution, and sale of cannabis and cannabis-derivative products globally. Recently launched an English-language version of the Physician Experience Platform in collaboration with Copeia [8][9] Financial Performance - **SNDL Inc.**: Reported net revenue of $33.5 million in Q2 2025, an increase of $5.7 million from Q2 2024. Gross profit was $14.5 million, up by $8.2 million from the previous year. However, net loss increased to $38.5 million, up by $29.7 million from Q2 2024. Adjusted EBITDA improved to $1.7 million, a $12.7 million increase from Q2 2024 [6]